FTC Dems want section 5 used on drug prices

Spencer Parts

01 July 2019

Credit: iStock/okskaz

A Federal Trade Commission report on the agency’s authority to limit price increases for off-patent drugs has drawn disagreement from two commissioners.

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.

Subscribe now

Already have access? Login below

Spencer Parts

View full biography

Author

Tipline

Could have been an email: The Tipline for 1 December 2023
The Federal Trade Commission and House Judiciary Committee appear to be stuck in a stalemate regardless of whether their quarrel occurs in letters or public hearings. Pressed by Republican lawmakers about the FTC’s responses (or lack thereof) to various document demands, the commission’s director of congressional relations had very little to say. “I’m not able to provide that information today, but we're happy to continue talking to your staff,” Jeanne Bumpus said.
Take two: The Tipline for 30 November 2023
Lights, in camera, action: The Tipline for 29 November 2023